LENZ Therapeutics, Inc. LENZ

LENZ Company Overview

LENZ Therapeutics, Inc. is a clinical-stage ophthalmic biotechnology company focused on developing and commercializing prescription eye-drop therapies for presbyopia, the age-related loss of near vision that typically affects adults over 40. The company operates within the broader ophthalmology and specialty pharmaceuticals industries, with its primary focus on pupil-modulating therapies intended to improve near vision without corrective lenses or invasive procedures. Its core product candidates have been based on aceclidine, a selective muscarinic agonist historically studied in ophthalmic applications.

The company’s principal revenue and value drivers have centered on its presbyopia treatment programs, including LNZ100 and LNZ101, which were evaluated in late-stage clinical development. LENZ has positioned itself around once-daily ophthalmic treatments designed to deliver improved durability and tolerability relative to earlier presbyopia eye-drop products introduced in the market. The company evolved from a privately funded biotechnology business into a publicly traded company listed on Nasdaq under the ticker LENZ, with its development strategy supported by venture capital financing, clinical trial advancement, and public market capital raises.